St Peter WL, Guo H, Kabadi S, et al. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol. 2018;19:67.
Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017;18:345.
Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.
Bonomini M, Del Vecchio L, Sirolli V, Locatelli F. New treatment approaches for the anemia of CKD. Am J Kidney Dis. 2016;67:133–42.
Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631–4.
Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease: a systematic review and meta-analysis. PLoS ONE. 2016;11:e0158765.
Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE. 2014;9:e84943.
Centers for Disease Control and Prevention. Chronic kidney disease in the United States, 2019. 2019. https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html. Accessed 16 July 2020.
London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transpl. 2002;17(Suppl 1):29–36.
Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.
Awan AA, Walther CP, Richardson PA, Shah M, Winkelmayer WC, Navaneethan SD. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transpl. 2019. https://doi.org/10.1093/ndt/gfz192.
Toft G, Heide-Jorgensen U, van Haalen H, et al. Anemia and clinical outcomes in patients with non-dialysis dependent or dialysis dependent severe chronic kidney disease: a Danish population-based study. J Nephrol. 2020;33:147–56.
Iimori S, Naito S, Noda Y, et al. Anaemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: The CKD-ROUTE study. Nephrology. 2015;20:601–8.
Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int. 2003;64:610–5.
Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. J Am Soc Nephrol. 2005;16:3403–10.
Lee G, Choi S, Kim K, et al. Association of hemoglobin concentration and its change with cardiovascular and all-cause mortality. J Am Heart Assoc. 2018;7:e007723.
Kim-Mitsuyama S, Soejima H, Yasuda O, et al. Anemia is an independent risk factor for cardiovascular and renal events in hypertensive outpatients with well-controlled blood pressure: a subgroup analysis of the ATTEMPT-CVD randomized trial. Hypertens Res. 2019;42:883–91.
Zoppini G, Targher G, Chonchol M, et al. Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. Atherosclerosis. 2010;210:575–80.
Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis. 2018;71:423–35.
Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–98.
Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.
Mukhopadhyay P, Sinha U, Banerjee J, Choudhury AR, Philips CA. The effects in correction of anaemia in chronic kidney disease with erythropoietin therapy–preference to cardiovascular, neurologic and general well-being of patients from a tertiary care centre. J Indian Med Assoc. 2012;110:885–8.
Covic A, Jackson J, Hadfield A, Pike J, Siriopol D. Real-world impact of cardiovascular disease and anemia on quality of life and productivity in patients with non-dialysis-dependent chronic kidney disease. Adv Ther. 2017;34:1662–72.
Finkelstein FO, Wuerth D, Finkelstein SH. Health related quality of life and the CKD patient: challenges for the nephrology community. Kidney Int. 2009;76:946–52.
Rao M, Pereira BJ. Optimal anemia management reduces cardiovascular morbidity, mortality, and costs in chronic kidney disease. Kidney Int. 2005;68:1432–8.
Garlo K, Williams D, Lucas L, et al. Severity of anemia predicts hospital length of stay but not readmission in patients with chronic kidney disease: a retrospective cohort study. Medicine (Baltimore). 2015;94:e964.
Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother. 2007;41:1761–9.
Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm. 2005;11:565–74.
Arantes LH Jr, Crawford J, Gascon P, et al. A quick scoping review of efficacy, safety, economic, and health-related quality-of-life outcomes of short- and long-acting erythropoiesis-stimulating agents in the treatment of chemotherapy-induced anemia and chronic kidney disease anemia. Crit Rev Oncol Hematol. 2018;129:79–90.
Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transpl. 2004;19:121–32.
Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol. 1991;1:990–8.
Rosati A, Ravaglia F, Panichi V. Improving erythropoiesis stimulating agent hyporesponsiveness in hemodialysis patients: the role of hepcidin and hemodiafiltration online. Blood Purif. 2018;45:139–46.
Sinha SD, Bandi VK, Bheemareddy BR, et al. Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial. BMC Nephrol. 2019;20:90.
Woodland AL, Murphy SW, Curtis BM, Barrett BJ. Costs associated with intravenous darbepoetin versus epoetin therapy in hemodialysis patients: a randomized controlled trial. Can J Kidney Health Dis. 2017;4:2054358117716461.
Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381:1011–22.
Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69:815–26.
Kaplan JM, Sharma N, Dikdan S. Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease. Int J Mol Sci. 2018;19:E389.
Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. 2019;30:1037–48.
Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989;299:157–8.
Agarwal R. Nonhematological benefits of iron. Am J Nephrol. 2007;27:565–71.
Hayat A. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Clin Med Res. 2008;6:93–102.
Macdougall IC, Bircher AJ, Eckardt KU, et al. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int. 2016;89:28–39.
Vaziri ND. Safety issues in iron treatment in CKD. Semin Nephrol. 2016;36:112–8.
Macdougall IC, Vernon K. Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol. 2017;45:60–2.
Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA. 2015;314:2062–8.
Roger SD. Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease. Clin Kidney J. 2017;10:i9–i15.
Kaushik T, Yaqoob MM. Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis. Biologics. 2013;7:243–6.
U.S. Food and Drug Administration. FDA drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. 2011. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-modified-dosing-recommendations-improve-safe-use-erythropoiesis. Accessed 23 July 2020.
Goodkin DA, Fuller DS, Robinson BM, et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol. 2011;22:358–65.
Akaishi M, Hiroe M, Hada Y, et al. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease. J Cardiol. 2013;62:249–56.
Hayashi T, Uemura Y, Kumagai M, et al. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA Clinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study). Clin Exp Nephrol. 2019;23:349–61.
Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194–207.
Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84.
Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363:1146–55.
Park H, Liu X, Henry L, Harman J, Ross EA. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006–2015). BMC Nephrol. 2018;19:318.
Li S, Guo H, Kabadi S, et al. Unexpected medical consequences of revised ESA label in non-dialysis-dependent chronic kidney disease patients with anemia. J Am Soc Nephrol. 2016;27:814A.
Collister D, Komenda P, Hiebert B, et al. The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2016;164:472–8.
Spinowitz B, Pecoits-Filho R, Winkelmayer WC, et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019;22:593–604.
Johansen KL, Finkelstein FO, Revicki DA, et al. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transpl. 2012;27:2418–25.
Muirhead N, Keown PA, Churchill DN, et al. Dialysis patients treated with Epoetin alpha show improved exercise tolerance and physical function: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int. 2011;15:87–94.
Fox KM, Yee J, Cong Z, et al. Transfusion burden in non-dialysis chronic kidney disease patients with persistent anemia treated in routine clinical practice: a retrospective observational study. BMC Nephrol. 2012;13:5.
Bohlius J, Bohlke K, Castelli R, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019;3:1197–210.
Lattanzio F, Corsonello A, Montesanto A, et al. Disentangling the impact of chronic kidney disease, anemia, and mobility limitation on mortality in older patients discharged from hospital. J Gerontol A Biol Sci Med Sci. 2015;70:1120–7.
Kuragano T, Mizusaki K, Kimura T, Nakanishi T. Anemia management considering the pathophysiology of elderly chronic kidney disease patients. Contrib Nephrol. 2019;198:135–43.
Dousdampanis P, Trigka K, Fourtounas C. Prevalence of anemia in patients with type II diabetes and mild to moderate chronic kidney disease and the impact of anti-RAS medications. Saudi J Kidney Dis Transpl. 2014;25:552–7.
Pappa M, Dounousi E, Duni A, Katopodis K. Less known pathophysiological mechanisms of anemia in patients with diabetic nephropathy. Int Urol Nephrol. 2015;47:1365–72.
Fujita Y, Doi Y, Hamano T, et al. Low erythropoietin levels predict faster renal function decline in diabetic patients with anemia: a prospective cohort study. Sci Rep. 2019;9:14871.
Stevens PE. Anaemia, diabetes and chronic kidney disease: where are we now? J Ren Care. 2012;38(Suppl 1):67–77.
Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care. 2009;32:1320–6.
Winocour PH. Diabetes and chronic kidney disease: an increasingly common multi-morbid disease in need of a paradigm shift in care. Diabet Med. 2018;35:300–5.
Fowler MJ. Microvascular and macrovascular complications of diabetes. Clinical Diabetes. 2008;26:77–82.
Bajaj S, Makkar BM, Abichandani VK, et al. Management of anemia in patients with diabetic kidney disease: a consensus statement. Indian J Endocrinol Metab. 2016;20:268–81.
Portoles J, Gorriz JL, Rubio E, et al. The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. BMC Nephrol. 2013;14:2.
Moss AH, Davison SN. How the ESRD quality incentive program could potentially improve quality of life for patients on dialysis. Clin J Am Soc Nephrol. 2015;10:888–93.
Valliant A, Hofmann RM. Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. Int J Nanomedicine. 2013;8:3297–307.
Rostoker G, Griuncelli M, Loridon C, et al. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125(991–9):e1.
Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–90.
Gafter-Gvili A, Ayalon-Dangur I, Cooper L, et al. Posttransplantation anemia in kidney transplant recipients: a retrospective cohort study. Medicine (Baltimore). 2017;96:e7735.
Gurlek Demirci B, Sezer S, Sayin CB, et al. Post-transplantation anemia predicts cardiovascular morbidity and poor graft function in kidney transplant recipients. Transpl Proc. 2015;47:1178–81.
Tsujita M, Kosugi T, Goto N, et al. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transpl. 2019;34:1409–16.
Kitamura K, Nakai K, Fujii H, Ishimura T, Fujisawa M, Nishi S. Pre-transplant erythropoiesis-stimulating agent hypo-responsiveness and post-transplant anemia. Transpl Proc. 2015;47:1820–4.
Haase VH. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int. 2017;21(Suppl 1):S110–S12424.
Del Balzo U, Signore PE, Walkinshaw G, et al. Nonclinical characterization of the HIF-prolyl hydroxylase inhibitor roxadustat, a novel treatment for anemia of chronic kidney disease. J Pharmacol Exp Ther. 2020. https://doi.org/10.1124/jpet.120.265181.
Kato S, Ochiai N, Takano H, et al. TP0463518, a novel prolyl hydroxylase inhibitor, specifically induces erythropoietin production in the liver. J Pharmacol Exp Ther. 2019;371:675–83.
Shah YM, Matsubara T, Ito S, Yim SH, Gonzalez FJ. Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. Cell Metab. 2009;9:152–64.
Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transpl. 2017;32:1373–86.
Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67:912–24.
Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27:1225–333.
Akizawa T, Ueno M, Shiga T, Reusch M. Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies. Ther Apher Dial. 2019. https://doi.org/10.1111/1744-9987.13468.
Charytan C, Manllo-Karim R, Martin ER, et al. SIERRAS: a phase 3, open-label, randomized, active-controlled study of the efficacy and safety of roxadustat in the maintenance treatment of anemia in subjects with ESRD on stable dialysis [abstract SA-PO227]. J Am Soc Nephrol. 2019;30:822.
Fishbane S, Pollock CA, El-Shahawy MA, et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients [abstract TH-OR022]. J Am Soc Nephrol. 2019;30:6.
Esposito C, Csiky B, Tataradze A, Reusch M, Han C, Sulowicz W. Two phase 3, multicenter, randomized studies of intermittent oral roxadustat in anemic CKD patients on (PYRENEES) and not on (ALPS) dialysis [abstract SA-PO225]. J Am Soc Nephrol. 2019;30:822.
Provenzano R, Evgeny S, Liubov E, et al. HIMALAYAS: a phase 3, randomized, open-label, active-controlled study of the efficacy and safety of roxadustat in the treatment of anemia in incident-dialysis patients [abstract TH-OR021]. J Am Soc Nephrol. 2019;30:5.
Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol. 2016;11:982–91.
Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transpl. 2015;30:1665–733.
Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019;381:1001–100.
Coyne DW, Roger SD, Shin SK, et al. ANDES: a phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis [abstract SA-PO228]. J Am Soc Nephrol. 2019;30:822–3.
Fishbane S, El-Shahawy MA, Pecoits-Filho R, et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia [abstract TH-OR023]. J Am Soc Nephrol. 2019;30:6.
Akizawa T, Tsubakihara Y, Nangaku M, et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in japanese hemodialysis subjects. Am J Nephrol. 2017;45:127–35.
Holdstock L, Meadowcroft AM, Maier R, et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016;27:1234–44.
Cizman B, Sykes AP, Paul G, Zeig S, Cobitz AR. An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects. Kidney Int Rep. 2018;3:841–50.
Meadowcroft AM, Cizman B, Holdstock L, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019;12:139–48.
Tsubakihara Y, Akizawa T, Nangaku M, et al. A 24-week anemia correction study of daprodustat in japanese dialysis patients. Ther Apher Dial. 2020;24:108–14.
Holdstock L, Cizman B, Meadowcroft AM, et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 2019;12:129–38.
Brigandi RA, Johnson B, Oei C, et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016;67:861–71.
Haase VH, Chertow GM, Block GA, et al. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transpl. 2019;34:90–9.
Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90:1115–22.
Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45:380–8.
Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol. 2019;14:28–39.
Akizawa T, Macdougall IC, Berns JS, et al. Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: DIALOGUE extension studies. Am J Nephrol. 2019;49:271–80.
Akizawa T, Nangaku M, Yamaguchi T, et al. Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial. Nephron. 2019;143:77–85.
Akizawa T, Nangaku M, Yamaguchi T, et al. A placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial. Am J Nephrol. 2019;49:165–74.
Parmar DV, Kansagra KA, Patel JC, et al. Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study. Am J Nephrol. 2019;49:470–8.
Shibata T, Nomura Y, Takada A, Aoki S, Katashima M, Murakami H. Evaluation of the effect of lanthanum carbonate hydrate on the pharmacokinetics of roxadustat in non-elderly healthy adult male subjects. J Clin Pharm Ther. 2018;43:633–9.
Shibata T, Nomura Y, Takada A, et al. Evaluation of food and spherical carbon adsorbent effects on the pharmacokinetics of roxadustat in healthy nonelderly adult male Japanese subjects. Clin Pharmacol Drug Dev. 2019;8:304–13.
Groenendaal-van de Meent D, Adel MD, et al. Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Clin Drug Investig. 2016;36:743–51.
Hara K, Takahashi N, Wakamatsu A, Caltabiano S. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015;30:410–8.
Buch A, Maroni BJ, Hartman CS. Dose exposure relationship of AKB-6548 is independent of the level of renal function. J Am Soc Nephrol. 2015;26:747A.
Bottcher M, Lentini S, Arens ER, et al. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. Br J Clin Pharmacol. 2018;84:1557–655.
Kansagra KA, Parmar D, Jani RH, et al. Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. Clin Pharmacokinet. 2018;57:87–102.
Astellas. Evrenzo® (roxadustat) tablets approved in Japan for the treatment of anemia associated with chronic kidney disease in dialysis patients. 2019. https://www.astellas.com/en/news/15096. Accessed 23 July 2020.
AstraZeneca. Roxadustat approved in China for the treatment of anaemia in non-dialysis-dependent patients with chronic kidney disease. 2019. https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-approved-in-china-for-the-treatment-of-anaemia-in-non-dialysis-dependent-patients-with-chronic-kidney-disease-22082019.html. Accessed 23 July 2020.
Akebia Therapeutics. Akebia Therapeutics announces approval of vadadustat in Japan for the treatment of anemia due to chronic kidney disease in dialysis-dependent and non-dialysis dependent adult patients. 2020. https://ir.akebia.com/press-releases. Accessed 23 July 2020.
GlaxoSmithKline. GSK receives first regulatory approval for Duvroq (daprodustat) in Japan for patients with anaemia due to chronic kidney disease. 2020. https://www.gsk.com/en-gb/media/press-releases. Accessed 23 July 2020.
Barratt J, Andrić B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomised, open-label, active-controlled study [abstract MO001]. Nephrol Dial Transpl. 2020;35:101–2.
Nangaku M, Kondo K, Kokado Y, et al. Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan [abstract SA-PO229]. J Am Soc Nephrol. 2019;30:823.
Nangaku M, Kondo K, Ueta K, et al. Randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan [abstract TH-OR024]. J Am Soc Nephrol. 2019;30:6.
ClinicalTrials.gov. Safety and efficacy study of roxadustat to treat anemia in patients with chronic kidney disease (CKD), not on dialysis. 2019. https://clinicaltrials.gov/ct2/show/NCT02174627. Accessed 23 July 2020.
ClinicalTrials.gov. Safety and efficacy study of roxadustat to treat anemia in patients with chronic kidney disease, on dialysis. 2019. https://clinicaltrials.gov/ct2/show/NCT02174731. Accessed 23 July 2020.
Provenzano R, Fishbane S, Wei L-J, et al. Pooled efficacy and cardiovascular (CV) analyses of roxadustat in the treatment of anemia in CKD patients on and not on dialysis [abstract FR-OR131]. J Am Soc Nephrol. 2019;30:B1.
Beck J, Henschel C, Chou J, Lin A, Del Balzo U. Evaluation of the carcinogenic potential of Roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats. Int J Toxicol. 2017;36:427–39.
Seeley TW, Sternlicht MD, Klaus SJ, Neff TB, Liu DY. Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia. 2017;5:1–9.
Dhillon S. Roxadustat: first global approval. Drugs. 2019;79:563–72.
Hu Z, Tao H, Shi A, Pan J. The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis. Expert Rev Pharmacoecon Outcomes Res. 2020;20:411–8.
Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology. 2007;12:321–30.
Rankin EB, Rha J, Selak MA, et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol. 2009;29:4527–38.
Chow A, Gervasi D, Guo G, Signore P, del Balzo U, Walkinshaw G. Roxadustat enhances degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) in a HIF and INSIG dependent manner. Keystone Symposia; January 19–23 2020; Keystone, CO.
The White House. Executive Order on Advancing American Kidney Health. 2019. https://www.whitehouse.gov/presidential-actions/executive-order-advancing-american-kidney-health/. Accessed 23 July 2020.
Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007;298:1291–9.
Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002;61:2235–9.
Akizawa T, Otsuka T, Reusch M, Ueno M. Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter. Open-Label Study Ther Apher Dial. 2020;24:115–25.
Caltabiano S, Cizman B, Burns O, et al. Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clin Kidney J. 2019;12:693–701.